An innate immune checkpoint in cancer immunotherapy

癌症免疫治疗中的先天免疫检查点

基本信息

  • 批准号:
    10286793
  • 负责人:
  • 金额:
    $ 41.55万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-03-01 至 2023-02-28
  • 项目状态:
    已结题

项目摘要

Our application is a pilot project focused on eliminating unexpected adverse effects of cancer therapeutics by uncovering health risk of a new class of immunotherapeutics that are in clinical and preclinical development. Receptor tyrosine kinase (RTK) genes Tyro3, Axl and Mertk are paralogs that have been newly characterized as “innate immune checkpoints”. The blockade of this class of RTKs is in development as immunotherapies that can boost anti-tumor immune response. However, here we provide preliminary data that some paralogs are expressed in astrocytes and microglia in the brain, and are functionally important for the maintenance of brain health and neurocognitive functions. Specifically, loss of function of Mertk and Axl in astrocytes did not affect early postnatal brain development (P45), but astrocytes expressed unfolded protein response-genes in mice by 3-months of age, concomitant with these astrocytes undergoing spontaneous activation. By 9-months of age, we observed lipofuscin accumulation in the brain. Although performance in learning and memory tasks was normal at 3- and 6-months of age, 9-month old mice displayed defects in hippocampus-dependent learning and memory. Furthermore, we also observed that ablation of Axl in microglia in an Alzheimer's Disease (AD) mouse model (5xFAD mouse) accelerated learning and memory defects in these mice. In light of this novel knowledge of the functional requirement AXL and MERTK in the brain, we believe it is imperative to fully investigate if targeting the kinase activity of these RTKs can have adverse neurocognitive effects. Since kinases primarily function through their enzymatic activity to phosphorylate substrates, we are choosing to take this approach first. Therefore, our application also includes the development of a new resource – AXL kinase- dead or AxlKD mouse. A MertkKD is already available in our laboratory. We will use these mouse models to investigate the effect of targeting kinase function in brain homeostasis, and learning and memory. We will also investigate AXL function in the context of an AD mouse model. Notably, our approach is essentially identical with the approach used to generate the preliminary data. The same set of experiments included in the preliminary data will be performed on MertkKD and/or AxlKD mice. We will perform the assays at various ages to characterize the age-dependent onset of the phenotypes. Observed histological changes in the brain in the MertkKD and/or AxlKD mice, along with behavioral changes in the animal, will not only provide a novel understanding of MERTK and AXL kinase in the brain health and neurocognitive function, but will also provide a rationale for developing brain-excluded therapeutics for AXL- and/or MERTK-based tumor immunotherapy. Kinase-independent, scaffold-functions of kinases have also been described to exist. This will be pursued in the future if our studies fail to reveal the phenotype observed with genetic knockout of Axl or that of Axl and Mertk.
我们的应用程序是一个试点项目,重点是通过以下方式消除癌症治疗的意外副作用 揭示处于临床和临床前开发阶段的新型免疫疗法的健康风险。 受体酪氨酸激酶 (RTK) 基因 Tyro3、Axl 和 Mertk 是新近鉴定的旁系同源基因 作为“先天免疫检查点”。此类 RTK 的阻断正在作为免疫疗法进行开发 可以增强抗肿瘤免疫反应。然而,在这里我们提供了一些旁系同源物的初步数据 在大脑中的星形胶质细胞和小胶质细胞中表达,对于维持 大脑健康和神经认知功能。具体来说,星形胶质细胞中 Mertk 和 Axl 功能的丧失并没有 影响出生后早期大脑发育(P45),但星形胶质细胞在 3个月大的小鼠,伴随着这些星形胶质细胞的自发激活。 9个月大时 随着年龄的增长,我们观察到脂褐质在大脑中积累。尽管学习和记忆任务的表现 3 个月和 6 个月大时正常,9 个月大的小鼠表现出海马依赖性缺陷 学习和记忆。此外,我们还观察到,阿尔茨海默病患者小胶质细胞中 Axl 的消融 疾病 (AD) 小鼠模型(5xFAD 小鼠)加速了这些小鼠的学习和记忆缺陷。鉴于 关于大脑中 AXL 和 MERTK 功能需求的新知识,我们认为有必要 全面调查针对这些 RTK 的激酶活性是否会对神经认知产生不良影响。自从 激酶主要通过其酶活性来磷酸化底物,我们选择采取 首先采用这种方法。因此,我们的应用还包括开发一种新资源——AXL激酶—— 死老鼠或 AxlKD 老鼠。我们的实验室已提供 MertkKD。我们将使用这些鼠标模型来 研究靶向激酶功能对大脑稳态以及学习和记忆的影响。我们还将 研究 AD 小鼠模型中的 AXL 功能。值得注意的是,我们的方法本质上是相同的 使用用于生成初步数据的方法。同一组实验包含在 初步数据将在 MertkKD 和/或 AxlKD 小鼠上进行。我们将在不同年龄进行测定 表征表型的年龄依赖性发病。观察到大脑的组织学变化 MertkKD 和/或 AxlKD 小鼠以及动物的行为变化不仅将提供一种新的 了解 MERTK 和 AXL 激酶在大脑健康和神经认知功能中的作用,同时也将提供 为基于 AXL 和/或 MERTK 的肿瘤免疫疗法开发脑排除疗法的基本原理。 也已描述存在不依赖于激酶的激酶支架功能。这将在 如果我们的研究未能揭示 Axl 基因敲除或 Axl 基因敲除观察到的表型,那么未来 默特克。

项目成果

期刊论文数量(22)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Chronicles of Cell Death Foretold: Specificities in the Mechanism of Disposal.
  • DOI:
    10.3389/fimmu.2017.01743
  • 发表时间:
    2017
  • 期刊:
  • 影响因子:
    7.3
  • 作者:
    Hughes LD;Bosurgi L;Ghosh S;Rothlin CV
  • 通讯作者:
    Rothlin CV
Determining the effector response to cell death.
  • DOI:
    10.1038/s41577-020-00456-0
  • 发表时间:
    2021-05
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Rothlin CV;Hille TD;Ghosh S
  • 通讯作者:
    Ghosh S
Coagulopathies and inflammatory diseases: '…glimpse of a Snark'.
凝血病和炎症性疾病:“蛇鲨的一瞥”。
  • DOI:
    10.1016/j.coi.2018.09.005
  • 发表时间:
    2018
  • 期刊:
  • 影响因子:
    7
  • 作者:
    DelCarmen,Silvina;Hapak,SophieM;Ghosh,Sourav;Rothlin,CarlaV
  • 通讯作者:
    Rothlin,CarlaV
When aging gets on the way of disposal: Senescent cell suppression of efferocytosis.
Cracking the Cell Death Code.
破解细胞死亡密码。
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sourav Ghosh其他文献

Sourav Ghosh的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sourav Ghosh', 18)}}的其他基金

Augmenting AXL and MERTK function to restrain cognitive decline and improve health span in mouse models of Alzheimer's Disease
增强 AXL 和 MERTK 功能以抑制阿尔茨海默氏病小鼠模型的认知衰退并改善健康寿命
  • 批准号:
    10662677
  • 财政年份:
    2023
  • 资助金额:
    $ 41.55万
  • 项目类别:
Naïve T cell archetypes and anti-tumor immunity
幼稚 T 细胞原型和抗肿瘤免疫
  • 批准号:
    10741153
  • 财政年份:
    2023
  • 资助金额:
    $ 41.55万
  • 项目类别:
Sex-Specific Single Cell Expression Profiles, Genetic Risk and Drug Responsiveness in Alzheimer's Disease
阿尔茨海默病的性别特异性单细胞表达谱、遗传风险和药物反应
  • 批准号:
    10467589
  • 财政年份:
    2021
  • 资助金额:
    $ 41.55万
  • 项目类别:
An innate immune checkpoint in cancer immunotherapy
癌症免疫治疗中的先天免疫检查点
  • 批准号:
    9447148
  • 财政年份:
    2017
  • 资助金额:
    $ 41.55万
  • 项目类别:
Apical-basal polarity signaling in glioblastoma
胶质母细胞瘤中的顶端-基底极性信号传导
  • 批准号:
    8657870
  • 财政年份:
    2010
  • 资助金额:
    $ 41.55万
  • 项目类别:
Apical-basal polarity signaling in glioblastoma
胶质母细胞瘤中的顶端-基底极性信号传导
  • 批准号:
    8461275
  • 财政年份:
    2010
  • 资助金额:
    $ 41.55万
  • 项目类别:
Apical-basal polarity signaling in glioblastoma
胶质母细胞瘤中的顶底极性信号传导
  • 批准号:
    8817344
  • 财政年份:
    2010
  • 资助金额:
    $ 41.55万
  • 项目类别:
Apical-basal polarity signaling in glioblastoma
胶质母细胞瘤中的顶底极性信号传导
  • 批准号:
    8915298
  • 财政年份:
    2010
  • 资助金额:
    $ 41.55万
  • 项目类别:
Apical-basal polarity signaling in glioblastoma
胶质母细胞瘤中的顶端-基底极性信号传导
  • 批准号:
    8649817
  • 财政年份:
    2010
  • 资助金额:
    $ 41.55万
  • 项目类别:
Apical-basal polarity signaling in glioblastoma
胶质母细胞瘤中的顶端-基底极性信号传导
  • 批准号:
    8527897
  • 财政年份:
    2010
  • 资助金额:
    $ 41.55万
  • 项目类别:

相似海外基金

EXCESS: The role of excess topography and peak ground acceleration on earthquake-preconditioning of landslides
过量:过量地形和峰值地面加速度对滑坡地震预处理的作用
  • 批准号:
    NE/Y000080/1
  • 财政年份:
    2024
  • 资助金额:
    $ 41.55万
  • 项目类别:
    Research Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
  • 批准号:
    2328975
  • 财政年份:
    2024
  • 资助金额:
    $ 41.55万
  • 项目类别:
    Continuing Grant
SHINE: Origin and Evolution of Compressible Fluctuations in the Solar Wind and Their Role in Solar Wind Heating and Acceleration
SHINE:太阳风可压缩脉动的起源和演化及其在太阳风加热和加速中的作用
  • 批准号:
    2400967
  • 财政年份:
    2024
  • 资助金额:
    $ 41.55万
  • 项目类别:
    Standard Grant
Market Entry Acceleration of the Murb Wind Turbine into Remote Telecoms Power
默布风力涡轮机加速进入远程电信电力市场
  • 批准号:
    10112700
  • 财政年份:
    2024
  • 资助金额:
    $ 41.55万
  • 项目类别:
    Collaborative R&D
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
  • 批准号:
    2328973
  • 财政年份:
    2024
  • 资助金额:
    $ 41.55万
  • 项目类别:
    Continuing Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
  • 批准号:
    2328972
  • 财政年份:
    2024
  • 资助金额:
    $ 41.55万
  • 项目类别:
    Continuing Grant
Collaborative Research: A new understanding of droplet breakup: hydrodynamic instability under complex acceleration
合作研究:对液滴破碎的新认识:复杂加速下的流体动力学不稳定性
  • 批准号:
    2332916
  • 财政年份:
    2024
  • 资助金额:
    $ 41.55万
  • 项目类别:
    Standard Grant
Collaborative Research: A new understanding of droplet breakup: hydrodynamic instability under complex acceleration
合作研究:对液滴破碎的新认识:复杂加速下的流体动力学不稳定性
  • 批准号:
    2332917
  • 财政年份:
    2024
  • 资助金额:
    $ 41.55万
  • 项目类别:
    Standard Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
  • 批准号:
    2328974
  • 财政年份:
    2024
  • 资助金额:
    $ 41.55万
  • 项目类别:
    Continuing Grant
Study of the Particle Acceleration and Transport in PWN through X-ray Spectro-polarimetry and GeV Gamma-ray Observtions
通过 X 射线光谱偏振法和 GeV 伽马射线观测研究 PWN 中的粒子加速和输运
  • 批准号:
    23H01186
  • 财政年份:
    2023
  • 资助金额:
    $ 41.55万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了